Ibrance (Palbociclib) is an advanced targeted therapy used in the treatment of HR-positive / HER2-negative breast cancer. It is one of the first and most important CDK4/6 inhibitors that transformed the management of this disease.
What is Ibrance ?
Ibrance belongs to a class of drugs called CDK4/6 inhibitors, which regulate cell division.
In hormone receptor-positive breast cancer, these enzymes are overactive, leading to uncontrolled tumor growth. Ibrance works by:
- Blocking cancer cell division
- Slowing tumor progression
- Enhancing the effectiveness of hormonal therapy
In simple terms:
It shuts down the cancer cell’s division cycle.
Indications
Ibrance (Palbociclib) is used in:
- HR-positive breast cancer
- HER2-negative cases
- Advanced or metastatic disease
- In combination with hormonal therapy such as Letrozole or Fulvestrant
Dosage and Administration
- Standard dose: 125 mg once daily
- Taken orally
- Treatment cycle: 21 days on treatment + 7 days off
- Should be taken at the same time every day
- Dose adjustments may be required based on blood counts
Common Side Effects
May include:
- Low white blood cell count (neutropenia)
- Fatigue
- Nausea
- Loss of appetite
- Mild hair thinning
- Increased risk of infections
These side effects are usually manageable with proper monitoring.
Monitoring During Treatment
Patients on Ibrance require:
- Regular complete blood count (CBC)
- Symptom monitoring
- Ongoing assessment of treatment response
Availability in Egypt
Ibrance is available in specialized oncology centers and major pharmacies in Egypt.
- It is a high-cost medication
- Requires close supervision by an oncology specialist
- Used Within modern treatment protocols
Importance of Ibrance
Ibrance is a key advancement because it:
- Directly targets the cell cycle
- Significantly slows disease progression
- Improves outcomes when combined with hormonal therapy
- Is widely used in global breast cancer treatment guidelines
Ibrance (Palbociclib) Ibrance (Palbociclib) 125 mg is an effective targeted therapy for HR-positive / HER2-negative breast cancer, helping to control disease progression and improve patient outcomes in advanced stages.
Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified oncology specialist.
